INHIBRX BIOSCIENCES, INC. Total Liabilities
INHIBRX BIOSCIENCES, INC. (INBX) had Total Liabilities of $207.20 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-13
- 2026-06-30: Liabilities $207.20M.
- 2026-03-31: Liabilities $205.00M.
- 2025-12-31: Liabilities $138.49M.
- 2025-09-30: Liabilities $140.64M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $207.20M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $205.00M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $138.49M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $140.64M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $143.56M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $148.20M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $47.18M 10-K · filed 2026-03-19 |
| 2024-09-30 | $44.09M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $39.05M 10-Q · filed 2024-08-13 |
| 2023-12-31 | $264.39M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |